Two privately-held American firms, Allumiqs and Prolytix, have announced a long-term, strategic partnership focused on “optimizing drug development pipelines.”
The companies will work together to deliver collaborative and integrated solutions for the biotech and biopharma sectors, offering bioanalytical solutions.
The partners will seek to advance drug candidates from the early R&D phases through to the development of finished products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze